Comparison Chart Akeso, Inc.

Equities

Delayed Hong Kong S.E. Other stock markets 07:12:37 04/06/2024 BST			5-day change	1st Jan Change
44 ^HKD	0.00%		+27.70%	-5.60%

05-31	Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%	MT
05-31	Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	AKESO, INC.	Bio Therapeutic Drugs	0.00%	+27.70%	-5.60%	+22.69%	-	4.87B